Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 48 Neoplasms 27 Colorectal Neoplasms 26 Neoplasm Metastasis 24 Recurrence 22 Ovarian Neoplasms 22 Pancreatic Neoplasms 21 Breast Neoplasms 20 Squamous Cell Carcinoma of Head and Neck 18 Prostatic Neoplasms 18 Melanoma 17 Glioblastoma 15 Lymphoma, Large B-Cell, Diffuse 14 Precursor Cell Lymphoblastic Leukemia-Lymphoma 13 Lymphoma, Non-Hodgkin 13 Endometrial Neoplasms 13 Multiple Myeloma 12 Lung Neoplasms 12 Colonic Neoplasms 12 Triple Negative Breast Neoplasms 11 Carcinoma, Renal Cell 11 Stomach Neoplasms 10 Leukemia, Myeloid, Acute 10 Glioma 10 Gastrointestinal Neoplasms 10 Rectal Neoplasms 9 Lymphoma, Follicular 9 Lymphoma 9 Head and Neck Neoplasms 8 Burkitt Lymphoma 8

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ovarian Cancer Recurrent × 30 days × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡